The efficacy of tadalafil in clinical populations

Ronald W Lewis, Richard Sadovsky, Ian Eardley, Michael O'Leary, Allen Seftel, Wei Christine Wang, Wei Shen, Daniel J. Walker, David G. Wong, Sanjeev Ahuja

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Objectives. To evaluate the efficacy of tadalafil in men with erectile dysfunction (ED) by demographic and ED characteristics, in patients having various comorbid medical conditions, and in patients receiving drug treatment for other medical conditions. Methods. This is an analysis of 11 double-blind, placebo-controlled trials with 2,102 men with a broad spectrum of ED etiology and various comorbid medical conditions as participants. The variables analyzed in this report included race, age, body mass index (BMI), ED etiology, ED severity, ED duration, smoking, prior sildenafil use, presence of comorbid conditions (diabetes mellitus, hypertension, cardiovascular disease, hyperlipidemia, depression, benign prostatic hyperplasia), and treatment with antihypertensives or antidepressants. Patients were randomly assigned to receive tadalafil 10 mg (N = 321), tadalafil 20 mg (N = 1,143), or placebo (N = 638). The primary efficacy variables included mean changes from baseline in the erectile function (EF) domain score of the International Index of Erectile Function (IIEF) questionnaire, and the mean per-patient percentage of "yes" responses to the Sexual Encounter Profile (SEP) diary question 3 (SEP3 - successful intercourse). The Global Assessment Question 1 (GAQ) was evaluated, as was the percentage of men attaining a normal IIEF EF domain score at end point. Results. Patients taking tadalafil 10 mg or 20 mg demonstrated significant improvement (P < 0.005) from baseline to end point on the IIEF EF domain score in all subpopulations analyzed compared with patients receiving placebo. The mean-per-patient percentage of "yes" responses to SEP3 increased significantly in all subpopulations taking tadalafil compared with placebo (P < 0.05). Tadalafil-treated patients had a significantly greater positive response rate on the GAQ in all subpopulations analyzed compared with placebo-treated patients (P < 0.03) except for the tadalafil 10 mg cardiovascular subpopulation (placebo, 46.8%; tadalafil 10 mg, 71.0%; P = 0.127). The percentage of positive responses ranged from 72% to 91% for patients on tadalafil 20 mg and from 52% to 94% for tadalafil 10 mg compared with a range of 20% to 47% for placebo-treated patients. Conclusions. Tadalafil was effective in improving erectile function across a wide spectrum of ED patients including patients with various comorbid conditions.

Original languageEnglish (US)
Pages (from-to)517-531
Number of pages15
JournalJournal of Sexual Medicine
Volume2
Issue number4
DOIs
StatePublished - Jan 1 2005

Fingerprint

Erectile Dysfunction
Population
Placebos
Tadalafil
Prostatic Hyperplasia
Hyperlipidemias
Antihypertensive Agents
Antidepressive Agents
Diabetes Mellitus
Body Mass Index
Cardiovascular Diseases
Smoking
Demography
Depression
Hypertension
Therapeutics
Pharmaceutical Preparations

Keywords

  • Clinical population
  • Erectile dysfunction
  • Tadalafil

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology
  • Urology

Cite this

Lewis, R. W., Sadovsky, R., Eardley, I., O'Leary, M., Seftel, A., Wang, W. C., ... Ahuja, S. (2005). The efficacy of tadalafil in clinical populations. Journal of Sexual Medicine, 2(4), 517-531. https://doi.org/10.1111/j.1743-6109.2005.00068.x

The efficacy of tadalafil in clinical populations. / Lewis, Ronald W; Sadovsky, Richard; Eardley, Ian; O'Leary, Michael; Seftel, Allen; Wang, Wei Christine; Shen, Wei; Walker, Daniel J.; Wong, David G.; Ahuja, Sanjeev.

In: Journal of Sexual Medicine, Vol. 2, No. 4, 01.01.2005, p. 517-531.

Research output: Contribution to journalArticle

Lewis, RW, Sadovsky, R, Eardley, I, O'Leary, M, Seftel, A, Wang, WC, Shen, W, Walker, DJ, Wong, DG & Ahuja, S 2005, 'The efficacy of tadalafil in clinical populations', Journal of Sexual Medicine, vol. 2, no. 4, pp. 517-531. https://doi.org/10.1111/j.1743-6109.2005.00068.x
Lewis RW, Sadovsky R, Eardley I, O'Leary M, Seftel A, Wang WC et al. The efficacy of tadalafil in clinical populations. Journal of Sexual Medicine. 2005 Jan 1;2(4):517-531. https://doi.org/10.1111/j.1743-6109.2005.00068.x
Lewis, Ronald W ; Sadovsky, Richard ; Eardley, Ian ; O'Leary, Michael ; Seftel, Allen ; Wang, Wei Christine ; Shen, Wei ; Walker, Daniel J. ; Wong, David G. ; Ahuja, Sanjeev. / The efficacy of tadalafil in clinical populations. In: Journal of Sexual Medicine. 2005 ; Vol. 2, No. 4. pp. 517-531.
@article{763b8b5e5f6a4bf98f3ea6e8ffad597e,
title = "The efficacy of tadalafil in clinical populations",
abstract = "Objectives. To evaluate the efficacy of tadalafil in men with erectile dysfunction (ED) by demographic and ED characteristics, in patients having various comorbid medical conditions, and in patients receiving drug treatment for other medical conditions. Methods. This is an analysis of 11 double-blind, placebo-controlled trials with 2,102 men with a broad spectrum of ED etiology and various comorbid medical conditions as participants. The variables analyzed in this report included race, age, body mass index (BMI), ED etiology, ED severity, ED duration, smoking, prior sildenafil use, presence of comorbid conditions (diabetes mellitus, hypertension, cardiovascular disease, hyperlipidemia, depression, benign prostatic hyperplasia), and treatment with antihypertensives or antidepressants. Patients were randomly assigned to receive tadalafil 10 mg (N = 321), tadalafil 20 mg (N = 1,143), or placebo (N = 638). The primary efficacy variables included mean changes from baseline in the erectile function (EF) domain score of the International Index of Erectile Function (IIEF) questionnaire, and the mean per-patient percentage of {"}yes{"} responses to the Sexual Encounter Profile (SEP) diary question 3 (SEP3 - successful intercourse). The Global Assessment Question 1 (GAQ) was evaluated, as was the percentage of men attaining a normal IIEF EF domain score at end point. Results. Patients taking tadalafil 10 mg or 20 mg demonstrated significant improvement (P < 0.005) from baseline to end point on the IIEF EF domain score in all subpopulations analyzed compared with patients receiving placebo. The mean-per-patient percentage of {"}yes{"} responses to SEP3 increased significantly in all subpopulations taking tadalafil compared with placebo (P < 0.05). Tadalafil-treated patients had a significantly greater positive response rate on the GAQ in all subpopulations analyzed compared with placebo-treated patients (P < 0.03) except for the tadalafil 10 mg cardiovascular subpopulation (placebo, 46.8{\%}; tadalafil 10 mg, 71.0{\%}; P = 0.127). The percentage of positive responses ranged from 72{\%} to 91{\%} for patients on tadalafil 20 mg and from 52{\%} to 94{\%} for tadalafil 10 mg compared with a range of 20{\%} to 47{\%} for placebo-treated patients. Conclusions. Tadalafil was effective in improving erectile function across a wide spectrum of ED patients including patients with various comorbid conditions.",
keywords = "Clinical population, Erectile dysfunction, Tadalafil",
author = "Lewis, {Ronald W} and Richard Sadovsky and Ian Eardley and Michael O'Leary and Allen Seftel and Wang, {Wei Christine} and Wei Shen and Walker, {Daniel J.} and Wong, {David G.} and Sanjeev Ahuja",
year = "2005",
month = "1",
day = "1",
doi = "10.1111/j.1743-6109.2005.00068.x",
language = "English (US)",
volume = "2",
pages = "517--531",
journal = "Journal of Sexual Medicine",
issn = "1743-6095",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - The efficacy of tadalafil in clinical populations

AU - Lewis, Ronald W

AU - Sadovsky, Richard

AU - Eardley, Ian

AU - O'Leary, Michael

AU - Seftel, Allen

AU - Wang, Wei Christine

AU - Shen, Wei

AU - Walker, Daniel J.

AU - Wong, David G.

AU - Ahuja, Sanjeev

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Objectives. To evaluate the efficacy of tadalafil in men with erectile dysfunction (ED) by demographic and ED characteristics, in patients having various comorbid medical conditions, and in patients receiving drug treatment for other medical conditions. Methods. This is an analysis of 11 double-blind, placebo-controlled trials with 2,102 men with a broad spectrum of ED etiology and various comorbid medical conditions as participants. The variables analyzed in this report included race, age, body mass index (BMI), ED etiology, ED severity, ED duration, smoking, prior sildenafil use, presence of comorbid conditions (diabetes mellitus, hypertension, cardiovascular disease, hyperlipidemia, depression, benign prostatic hyperplasia), and treatment with antihypertensives or antidepressants. Patients were randomly assigned to receive tadalafil 10 mg (N = 321), tadalafil 20 mg (N = 1,143), or placebo (N = 638). The primary efficacy variables included mean changes from baseline in the erectile function (EF) domain score of the International Index of Erectile Function (IIEF) questionnaire, and the mean per-patient percentage of "yes" responses to the Sexual Encounter Profile (SEP) diary question 3 (SEP3 - successful intercourse). The Global Assessment Question 1 (GAQ) was evaluated, as was the percentage of men attaining a normal IIEF EF domain score at end point. Results. Patients taking tadalafil 10 mg or 20 mg demonstrated significant improvement (P < 0.005) from baseline to end point on the IIEF EF domain score in all subpopulations analyzed compared with patients receiving placebo. The mean-per-patient percentage of "yes" responses to SEP3 increased significantly in all subpopulations taking tadalafil compared with placebo (P < 0.05). Tadalafil-treated patients had a significantly greater positive response rate on the GAQ in all subpopulations analyzed compared with placebo-treated patients (P < 0.03) except for the tadalafil 10 mg cardiovascular subpopulation (placebo, 46.8%; tadalafil 10 mg, 71.0%; P = 0.127). The percentage of positive responses ranged from 72% to 91% for patients on tadalafil 20 mg and from 52% to 94% for tadalafil 10 mg compared with a range of 20% to 47% for placebo-treated patients. Conclusions. Tadalafil was effective in improving erectile function across a wide spectrum of ED patients including patients with various comorbid conditions.

AB - Objectives. To evaluate the efficacy of tadalafil in men with erectile dysfunction (ED) by demographic and ED characteristics, in patients having various comorbid medical conditions, and in patients receiving drug treatment for other medical conditions. Methods. This is an analysis of 11 double-blind, placebo-controlled trials with 2,102 men with a broad spectrum of ED etiology and various comorbid medical conditions as participants. The variables analyzed in this report included race, age, body mass index (BMI), ED etiology, ED severity, ED duration, smoking, prior sildenafil use, presence of comorbid conditions (diabetes mellitus, hypertension, cardiovascular disease, hyperlipidemia, depression, benign prostatic hyperplasia), and treatment with antihypertensives or antidepressants. Patients were randomly assigned to receive tadalafil 10 mg (N = 321), tadalafil 20 mg (N = 1,143), or placebo (N = 638). The primary efficacy variables included mean changes from baseline in the erectile function (EF) domain score of the International Index of Erectile Function (IIEF) questionnaire, and the mean per-patient percentage of "yes" responses to the Sexual Encounter Profile (SEP) diary question 3 (SEP3 - successful intercourse). The Global Assessment Question 1 (GAQ) was evaluated, as was the percentage of men attaining a normal IIEF EF domain score at end point. Results. Patients taking tadalafil 10 mg or 20 mg demonstrated significant improvement (P < 0.005) from baseline to end point on the IIEF EF domain score in all subpopulations analyzed compared with patients receiving placebo. The mean-per-patient percentage of "yes" responses to SEP3 increased significantly in all subpopulations taking tadalafil compared with placebo (P < 0.05). Tadalafil-treated patients had a significantly greater positive response rate on the GAQ in all subpopulations analyzed compared with placebo-treated patients (P < 0.03) except for the tadalafil 10 mg cardiovascular subpopulation (placebo, 46.8%; tadalafil 10 mg, 71.0%; P = 0.127). The percentage of positive responses ranged from 72% to 91% for patients on tadalafil 20 mg and from 52% to 94% for tadalafil 10 mg compared with a range of 20% to 47% for placebo-treated patients. Conclusions. Tadalafil was effective in improving erectile function across a wide spectrum of ED patients including patients with various comorbid conditions.

KW - Clinical population

KW - Erectile dysfunction

KW - Tadalafil

UR - http://www.scopus.com/inward/record.url?scp=22144453867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144453867&partnerID=8YFLogxK

U2 - 10.1111/j.1743-6109.2005.00068.x

DO - 10.1111/j.1743-6109.2005.00068.x

M3 - Article

VL - 2

SP - 517

EP - 531

JO - Journal of Sexual Medicine

JF - Journal of Sexual Medicine

SN - 1743-6095

IS - 4

ER -